Loading...
Please wait, while we are loading the content...
Similar Documents
Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice
| Content Provider | Semantic Scholar |
|---|---|
| Author | Rocamora, Rodrigo Peltola, Jukka Assenza, Giovanni McMurray, Rob Villanueva, Vicente |
| Copyright Year | 2020 |
| Abstract | PURPOSE To assess the efficacy, safety and tolerability of eslicarbazepine acetate (ESL) in patients transitioning from carbamazepine or oxcarbazepine to ESL in clinical practice, by analysing data from the Euro-Esli study. METHODS Euro-Esli was a pooled analysis of 14 European clinical practice studies. Effectiveness assessments included responder rate (≥50 % seizure frequency reduction) and seizure freedom rate (seizure freedom at least since prior visit), assessed after 3, 6 and 12 months of ESL treatment, and at the last visit. Safety and tolerability were assessed throughout follow-up by evaluating adverse events (AEs) and ESL discontinuation due to AEs, respectively. Data were analysed for cohorts of patients who transitioned from carbamazepine and oxcarbazepine to ESL either due to lack of efficacy or poor tolerability. RESULTS Euro-Esli included 2058 patients, of whom 233 (11.3 %) transitioned from carbamazepine to ESL and 134 (6.5 %) transitioned from oxcarbazepine to ESL. After 12 months of ESL treatment, responder and seizure freedom rates for patients transitioning from carbamazepine due to lack of efficacy (n = 163) were 70.0 % and 30.9 %, respectively. Corresponding values for patients transitioning from oxcarbazepine due to lack of efficacy (n = 90) were 57.1 % and 25.0 %, respectively. Among patients who transitioned from carbamazepine and oxcarbazepine to ESL due to poor tolerability (n = 64 and n = 61, respectively), 26.6 % and 39.5 % experienced AEs, and 8.3 % and 6.8 % discontinued ESL due to AEs, respectively. CONCLUSION ESL was efficacious and generally well tolerated in patients transitioning from carbamazepine or oxcarbazepine in clinical practice due to inadequate seizure control or intolerable AEs with these agents. |
| Starting Page | 121 |
| Ending Page | 128 |
| Page Count | 8 |
| File Format | PDF HTM / HTML |
| DOI | 10.1016/j.seizure.2019.12.022 |
| PubMed reference number | 31981862 |
| Journal | Medline |
| Volume Number | 75 |
| Alternate Webpage(s) | https://api.elsevier.com/content/article/pii/S1059131119307812 |
| Alternate Webpage(s) | https://www.sciencedirect.com/science/article/pii/S1059131119307812?dgcid=api_sd_search-api-endpoint |
| Alternate Webpage(s) | https://doi.org/10.1016/j.seizure.2019.12.022 |
| Journal | Seizure |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
